OTX-BDI

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug NameOTX-BDI
Drug Alias NameBesifloxacin + dexamethasone (Ocular Therapeutix)OTX-BDI
ClassificationSmall molecules > Heterocyclic drugs > AntibioticsSmall molecules > Steroids
Mechanisms of ActionGlucocorticoid receptor agonistsInhibitor of NF-kappa-B kinase (IKK) modulatorsNuclear factor NF-kappa-B complex inhibitors +[4] 
TargetsGlucocorticoid receptorInterleukin-1 betaNuclear factor NF-kappa-B complex +[4] 
Therapy Area/IndicationsOcular inflammationEye PainEye Infections, Bacterial
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOcular Therapeutix Inc
China Registration ClassN/A

Develop Information

Active CompaniesOcular Therapeutix Inc
Inactive CompaniesN/A
Active IndicationsOcular inflammationEye PainEye Infections, Bacterial
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A